Zacks Investment Research on MSN

Editas Medicine (EDIT) reports Q4 loss, tops revenue estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.55 per share a year ago. These figures ...
Nasdaq

Editas Medicine, Inc. Common Stock (EDIT)

©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...